These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15089791)

  • 21. Flexible eating and flexible insulin dosing in patients with diabetes: Results of an intensive self-management course.
    Lowe J; Linjawi S; Mensch M; James K; Attia J
    Diabetes Res Clin Pract; 2008 Jun; 80(3):439-43. PubMed ID: 18353485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
    Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
    BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study.
    Wake N; Hisashige A; Katayama T; Kishikawa H; Ohkubo Y; Sakai M; Araki E; Shichiri M
    Diabetes Res Clin Pract; 2000 Jun; 48(3):201-10. PubMed ID: 10802159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.
    Grima DT; Thompson MF; Sauriol L
    Pharmacoeconomics; 2007; 25(3):253-66. PubMed ID: 17335310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
    Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
    J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twice- rather than once-daily basal insulin is associated with better glycaemic control in Type 1 diabetes mellitus 12 months after skills-based structured education in insulin self-management.
    Hopkinson HE; Jacques RM; Gardner KJ; Amiel SA; Mansell P
    Diabet Med; 2015 Aug; 32(8):1071-6. PubMed ID: 25982032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The costs of helping patients with type 1 diabetes achieve tight control.
    Nuovo J; Nuovo J
    Am Fam Physician; 1999 Nov; 60(7):1914, 1920-1. PubMed ID: 10569496
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France.
    Roze S; Smith-Palmer J; Valentine W; Payet V; de Portu S; Papo N; Cucherat M; Hanaire H
    Diabetes Technol Ther; 2016 Feb; 18(2):75-84. PubMed ID: 26646072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes.
    Ly TT; Brnabic AJ; Eggleston A; Kolivos A; McBride ME; Schrover R; Jones TW
    Value Health; 2014 Jul; 17(5):561-9. PubMed ID: 25128049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
    Riemsma R; Corro Ramos I; Birnie R; Büyükkaramikli N; Armstrong N; Ryder S; Duffy S; Worthy G; Al M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Feb; 20(17):v-xxxi, 1-251. PubMed ID: 26933827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
    Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
    Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Educational guidelines for achieving tight control and minimizing complications of type 1 diabetes.
    Havas S
    Am Fam Physician; 1999 Nov; 60(7):1985-92, 1997-8. PubMed ID: 10569502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of glycemic variability in continuous subcutaneous insulin infusion therapy in type 1 diabetes related to anthropometry and complication status.
    Mehdi SK; Hatfield E; Dornhorst A; Oliver NS
    J Diabetes Sci Technol; 2009 Sep; 3(5):1227-8. PubMed ID: 20144442
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA
    McEwan P; Bennett H; Bolin K; Evans M; Bergenheim K
    Diabet Med; 2018 May; 35(5):557-566. PubMed ID: 29377320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flexible, intensive insulin therapy and dietary freedom in adolescents and young adults with Type 1 diabetes: a prospective implementation study.
    Sämann A; Lehmann T; Kloos C; Braun A; Hunger-Dathe W; Wolf G; Müller UA
    Diabet Med; 2008 May; 25(5):592-6. PubMed ID: 18445173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost calculation for a flash glucose monitoring system for UK adults with type 1 diabetes mellitus receiving intensive insulin treatment.
    Hellmund R; Weitgasser R; Blissett D
    Diabetes Res Clin Pract; 2018 Apr; 138():193-200. PubMed ID: 29410149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy.
    Haldrup S; Lapolla A; Gundgaard J; Wolden ML
    J Med Econ; 2020 Mar; 23(3):271-279. PubMed ID: 31526202
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Earlier intensified insulin treatment of Type 1 diabetes and its association with long-term macrovascular and renal complications.
    Rathsman B; Donner M; Ursing C; Nyström T
    Diabet Med; 2016 Apr; 33(4):463-70. PubMed ID: 26315152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.